Physician profile
Mary E Vann
NPI 1669855714
$9,453.73
in general payments reported to CMS, 2019-2025
44 companies · $1,819 in 2025
The $1,819 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,522 · 2022: $2,034 · 2023: $1,994 · 2024: $2,084 · 2025: $1,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,874 · Entertainment: $14.54 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,874.25 |
| Entertainment | $14.54 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,534.73 | 2021-2025 | |
| Novo Nordisk INC | $1,437.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,099.30 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $981.55 | 2021-2025 | |
| Lilly USA, LLC | $436.39 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $389.41 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $358.96 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $343.05 | 2022 | |
| Shield Therapeutics INC | $307.81 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $246.13 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.95 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $237.62 | 2021 | |
| Sanofi-Aventis U.S. LLC | $210.47 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.05 | 2022-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.58 | 2022-2025 | Caplyta |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $122.56 | 2021-2025 | Veozah |
| Dexcom, INC. | $90.51 | 2023-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $86.07 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $80.71 | 2021-2023 | Austedo |
| Novartis Pharmaceuticals Corporation | $73.96 | 2023-2024 | |
| Amgen INC. | $69.82 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $66.72 | 2021-2022 | |
| Esperion Therapeutics, INC. | $65.65 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $65.28 | 2021-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $63.51 | 2023-2024 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $54.59 | 2024-2025 | Auvelity |
| Phadia US INC. | $50.16 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $48.91 | 2021-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Takeda Pharmaceuticals U.S.A., INC. | $46.69 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $43.49 | 2021 | |
| Antares Pharma, INC. | $34.91 | 2024-2025 | Xyosted |
| Edwards Lifesciences Corporation | $32.18 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amneal Pharmaceuticals LLC | $31.02 | 2022-2025 | Unithroid |
| Boston Scientific Corporation | $22.10 | 2023 | Watchman Access System |
| Alexion Pharmaceuticals, INC. | $21.27 | 2024 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $20.87 | 2023 | Eliquis |
| Philips North America LLC | $18.81 | 2024 | (Ck6) Holter |
| Allergan, INC. | $16.22 | 2021 | |
| Genentech USA, INC. | $14.59 | 2021 | |
| Optos, INC. | $14.54 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Eisai INC. | $14.44 | 2021 | |
| Watermark Medical, INC. | $14.12 | 2024 | |
| Seqirus USA INC | $13.36 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.12 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Vann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.